Literature DB >> 8808916

Electromotive drug administration to the urinary bladder: an animal model and preliminary results.

T Gürpinar1, L D Truong, H Y Wong, D P Griffith.   

Abstract

PURPOSE: Electromotive drug delivery (EMDA) is the use of an electrical field to enhance penetration of ionized drugs into local tissues. Intraurinary EMDA may be of value in the treatment of various pathological conditions involving the urinary bladder, prostate gland and urethra. We have developed an animal model to study this hypothesis.
MATERIALS AND METHODS: Anesthetized adult mongrel dogs were studied. An intravesical anode was inserted through a Foley catheter into the urinary bladder. Two patch electrodes were positioned on the animals' abdominal skin. Both skin and intravesical electrodes were attached to a direct current generator. The bladder was then distended with an anionic blue dye (methylene blue). Fifteen milliamperes (15 mA) pulsed direct current was applied for 40 minutes. After EMDA, the bladder was surgically removed and representative sections of full thickness bladder wall were immediately frozen in liquid nitrogen. Methylene blue was used to visually demonstrate EMDA-enhanced anion penetration into bladder submucosa and muscularis. RESULT: This experimental model demonstrates significant submucosal and muscularis methylene blue penetration in the presence of the electric field.
CONCLUSION: Electromotive drug delivery technology may have applications for treating bladder pathology.

Entities:  

Mesh:

Year:  1996        PMID: 8808916

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  Recent advances in intravesical drug/gene delivery.

Authors:  Pradeep Tyagi; Pao-Chu Wu; Michael Chancellor; Naoki Yoshimura; Leaf Huang
Journal:  Mol Pharm       Date:  2006 Jul-Aug       Impact factor: 4.939

2.  A programmable iontophoretic instrument and its application for local anesthesia before surgery in urology.

Authors:  Mahmut Tokmakçi; Oguz Ekmekçioglu; Mustafa Alçi
Journal:  J Med Syst       Date:  2005-04       Impact factor: 4.460

3.  [Intravesical therapy for overactive bladder].

Authors:  J Pannek; U Grigoleit; R Wormland; M Goepel
Journal:  Urologe A       Date:  2006-02       Impact factor: 0.639

4.  Intravesical electromotive administration of botulinum toxin type A in improving the bladder and bowel functions: Evidence for novel mechanism of action.

Authors:  Abdol-Mohammad Kajbafzadeh; Hamed Ahmadi; Laleh Montaser-Kouhsari; Shabnam Sabetkish; Sanam Ladi-Seyedian; Masoud Sotoudeh
Journal:  J Spinal Cord Med       Date:  2019-04-18       Impact factor: 1.985

Review 5.  Adjuvant methods to improve results of local bladder irrigations by chemotherapy for NMIBC.

Authors:  Yuval Freifeld; Yoram Dekel; Avi Stein
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

6.  State of the art in intravesical therapy for lower urinary tract symptoms.

Authors:  Jonathan Kaufman; Vikas Tyagi; Michele Anthony; Michael B Chancellor; Pradeep Tyagi
Journal:  Rev Urol       Date:  2010

7.  Intravesical electromotive drug administration for the treatment of non-infectious chronic cystitis.

Authors:  C R Riedl; M Knoll; E Plas; R L Stephen; H Pflüger
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1997

Review 8.  Therapeutic Efficacy of onabotulinumtoxinA Delivered Using Various Approaches in Sensory Bladder Disorder.

Authors:  Po-Yen Chen; Wei-Chia Lee; Hung-Jen Wang; Yao-Chi Chuang
Journal:  Toxins (Basel)       Date:  2020-01-23       Impact factor: 4.546

9.  Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.

Authors:  Darryl T Martin; Christopher J Hoimes; Hristos Z Kaimakliotis; Christopher J Cheng; Ke Zhang; Jingchun Liu; Marcia A Wheeler; W Kevin Kelly; Greg N Tew; W Mark Saltzman; Robert M Weiss
Journal:  Nanomedicine       Date:  2013-06-11       Impact factor: 5.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.